Accella Advisors


Project: Company Due Diligence

       The problem
A German Biotech company ran into financial problems, primary clinical data of the most advanced product were insufficient and investors were not satisfied with the management performance. The investors asked for support.

The solution
A comprehensive strategical, technological, and management audit was performed and gaps identified. The CEO function was taken over interimistically.

The outcome
The business strategy was re-defined, the product portfolio streamlined and technology gaps were closed. The complete IP was merged into a listed international biotech company.

Reference project: Turnaround Management